Processing

Please wait...

Settings

Settings

1. WO2020014460 - HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF

Publication Number WO/2020/014460
Publication Date 16.01.2020
International Application No. PCT/US2019/041373
International Filing Date 11.07.2019
IPC
A61K 39/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 2039/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
60characteristics by the carrier linked to the antigen
A61K 2039/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
70Multivalent vaccine
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 2760/18234
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2760ssRNA Viruses negative-sense
00011ssRNA Viruses negative-sense
18011Paramyxoviridae
18211Henipavirus, e.g. hendra virus
18234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • SCHOLAR ROCK, INC. [US/US]; 620 Memorial Drive 2nd Floor Cambridge, MA 02139, US
Inventors
  • DATTA, Abhishek; US
  • CAPILI, Allan; US
  • SCHURPF, Thomas; US
  • MARTIN, Constance; US
  • DAGBAY, Kevin, B.; US
  • CHAPRON, Christopher; US
  • WAWERSIK, Stefan; US
  • LITTLEFIELD, Christopher; US
  • CARVEN, Gregory, J.; US
  • BUCKLER, Alan; US
  • LIN, Susan; US
  • JACKSON, Justin, W.; US
  • STEIN, Caitlin; US
  • AVERY, Andrew; US
  • COOPER, Anthony; US
  • SALOTTO, Matthew; US
Agents
  • CLARKE, Marcie, B.; US
  • BAI, Mei; US
  • BLAZESKI, George; US
  • BROWN, Ronald, E.; US
  • BOWLES, Anita, M.; US
Priority Data
62/696,75211.07.2018US
62/718,19613.08.2018US
62/737,53427.09.2018US
62/758,18009.11.2018US
62/810,26325.02.2019US
62/827,55201.04.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
(FR) INHIBITEURS DE TGFβ1 SÉLECTIFS SELON L'ISOFORME À AFFINITÉ ÉLEVÉE
Abstract
(EN)
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting ΤGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
(FR)
L'invention concerne des anticorps monoclonaux et des fragments de liaison à l'antigène de ceux-ci capables d'inhiber sélectivement ΤΟΡβ1 avec un pouvoir élevé. L'invention concerne également des compositions, des procédés et une utilisation thérapeutique associés.
Latest bibliographic data on file with the International Bureau